Tag: eosinophilic esophagitis (EoE)
Peptide Shows Promise as an Allergen-Agnostic Treatment for Food Allergy
Revolog presents new data demonstrating long-lasting effect of '1104 candidate.
Esophageal String Test®, a Less Invasive Way to Monitor Adults and...
Test offers EoE patients a simple, clinically proven method to control their disease.
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...
Majority of patients achieved histological disease remission in 16 weeks.
Diagnosis of 12-Year-Old Boy with Gene Defect Leads to New Avenues...
First description of the mutation in the human genome.
FDA Approves First Treatment for Eosinophilic Esophagitis (EoE), a Chronic Immune...
EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus.
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12...
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
CHOP Receives $2M Philanthropic Gift to Launch Food Allergy Study Using...
"A successful clinical trial would open the possibility of food introduction to more than 3,500 CHOP patients with EoE."
Revolo Biotherapeutics Announces Open Enrollment for Phase 2 Clinical Trial of...
Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.
Two UK Allergy Moms Who Suffered Horrific Losses Demand an Allergy...
We applaud the efforts of Ms Ednan-Laperouse and Ms Turay and believe their concept of a single person responsible for the health and safety of the allergic community should be adopted here in the US.
Dupixent (dupilumab) Study Shows Significant Improvement in Eosinophilic Esophagitis Signs and...
Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
